Loading...

FITC anti-human CD66b Antibody FITC anti-human CD66b Antibody

Pricing & Availability
Clone
G10F5 (See other available formats)
Regulatory Status
RUO
Workshop
VI MA81
Other Names
CD67, CGM6, NCA-95, CEACAM8
Isotype
Mouse IgM, κ
Ave. Rating
Submit a Review
Product Citations
publications
G10F5
Human peripheral whole blood granulocytes stained with G10F5 FITC
  • G10F5
    Human peripheral whole blood granulocytes stained with G10F5 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
305104 100 tests SEK1958
Check Availability


Need larger quantities of this item?
Request Bulk Quote
305103 25 tests SEK824
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD66b is a 95-100 kD glycosylphosphatidylinositol (GPI)-linked protein also known as CD67, CGM6, and NCA-95. CD66b is a member of the immunoglobulin superfamily, carcinoembryonic antigen (CEA)-like subfamily. CD66b, expressed on granulocytes, has been reported to induce activation in neutrophils and to be involved in heterophilic adhesion with CD66c.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen, formalin-fixed paraffin-embedded tissue sections, and spatial biology (IBEX)5,6.

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Kishimoto T, et al. Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. London.
  3. Norling LV, et al. 2012. Arterioscler Thromb Vasc Biol. 32:1970. PubMed
  4. Meinke P, et al. 2015. Neuroimmunol Discord. 25:127. PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Ackermann M, et al. 2018. Nat Commun. 9:5088. PubMed
  2. Stojkov D, et al. 2017. J Cell Biol. 216:4073. PubMed
  3. Nijnik A, et al. 2010. J Immunol. 184:2539. PubMed
  4. Guo Y, et al. 2021. Exp Ther Med. 353:21. PubMed
  5. Carre C, et al. 2021. iScience. 24:102970. PubMed
  6. Kfoury Y, et al. 2021. Cancer Cell. 39:1464. PubMed
  7. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  8. Mauracher LM, et al. 2023. Res Pract Thromb Haemost. 7:100126. PubMed
  9. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  10. Margaroli C, et al. 2021. Cell Reports Medicine. 2(4):100239. PubMed
  11. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  12. Schimek V, et al. 2022. Cell Death Dis. 13:113. PubMed
  13. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  14. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
  15. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  16. Reif T, et al. 2021. Cell Reports Medicine. 2(6):100317. PubMed
  17. Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
  18. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
  19. Appios A, et al. 2021. Bio Protoc. 11:e4044. PubMed
  20. Osorio FG et al. 2018. Cell reports. 25(9):2308-2316 . PubMed
  21. Heim C, et al. 2015. J Immunol. 194:3861. PubMed
  22. Callahan S, et al. 2020. Cell Microbiol. 22:e13210. PubMed
  23. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  24. Gomez I, et al. 2020. Nat Commun. 11:214. PubMed
  25. Miralda I, et al. 2020. Front Immunol. 11:497. PubMed
  26. Saha R, et al. 2021. Sci Rep. 11:18849. PubMed
  27. Simon SCS, et al. 2020. Oncoimmunology. 9:1727116. PubMed
  28. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  29. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  30. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  31. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  32. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  33. Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed
  34. Ozuna H, et al. 2021. Front Immunol. 12:707096. PubMed
  35. Fan Z, et al. 2020. STAR Protoc. 1:100012. PubMed
  36. Franco LM, et al. 2019. J Exp Med. 216:384. PubMed
  37. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  38. SenGupta S, et al. 2016. J Leukoc Biol. 100: 1047 - 1059. PubMed
  39. Rodriguez-Meira A, et al. 2020. STAR Protoc. 1:100125. PubMed
  40. Zhao Z, et al. 2019. J Immunol Res. 2019:9561350. PubMed
  41. Pulsifer AR, et al. 2020. Infect Immun. 88:00:00. PubMed
  42. Mueller-Leisse J, et al. 2015. Med Mycol. 53: 622-629. PubMed
  43. Pliyev B, et al. 2011. Cell Immunol. 271:214. PubMed
  44. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  45. Bonegio RG, et al. 2019. J Immunol. 202:675. PubMed
  46. Little M, et al. 2012. PLoS One. 7:e28626.. PubMed
  47. Rodriguez‐Meira A et al. 2019. Molecular cell. 73(6):1292-1305 . PubMed
  48. Ceglia V, et al. 2022. Front Immunol. 12:786144. PubMed
  49. Ackermann M, et al. 2018. Nat Commun. 9:5088. PubMed
  50. Stojkov D, et al. 2017. J Cell Biol. 216:4073. PubMed
  51. Nijnik A, et al. 2010. J Immunol. 184:2539. PubMed
  52. Guo Y, et al. 2021. Exp Ther Med. 353:21. PubMed
  53. Carre C, et al. 2021. iScience. 24:102970. PubMed
  54. Kfoury Y, et al. 2021. Cancer Cell. 39:1464. PubMed
  55. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  56. Mauracher LM, et al. 2023. Res Pract Thromb Haemost. 7:100126. PubMed
  57. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  58. Margaroli C, et al. 2021. Cell Reports Medicine. 2(4):100239. PubMed
  59. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  60. Schimek V, et al. 2022. Cell Death Dis. 13:113. PubMed
  61. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  62. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
  63. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  64. Reif T, et al. 2021. Cell Reports Medicine. 2(6):100317. PubMed
  65. Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
  66. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
  67. Appios A, et al. 2021. Bio Protoc. 11:e4044. PubMed
  68. Osorio FG et al. 2018. Cell reports. 25(9):2308-2316 . PubMed
  69. Heim C, et al. 2015. J Immunol. 194:3861. PubMed
  70. Callahan S, et al. 2020. Cell Microbiol. 22:e13210. PubMed
  71. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  72. Gomez I, et al. 2020. Nat Commun. 11:214. PubMed
  73. Miralda I, et al. 2020. Front Immunol. 11:497. PubMed
  74. Saha R, et al. 2021. Sci Rep. 11:18849. PubMed
  75. Simon SCS, et al. 2020. Oncoimmunology. 9:1727116. PubMed
  76. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  77. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  78. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  79. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  80. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  81. Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed
  82. Ozuna H, et al. 2021. Front Immunol. 12:707096. PubMed
  83. Fan Z, et al. 2020. STAR Protoc. 1:100012. PubMed
  84. Franco LM, et al. 2019. J Exp Med. 216:384. PubMed
  85. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  86. SenGupta S, et al. 2016. J Leukoc Biol. 100: 1047 - 1059. PubMed
  87. Rodriguez-Meira A, et al. 2020. STAR Protoc. 1:100125. PubMed
  88. Zhao Z, et al. 2019. J Immunol Res. 2019:9561350. PubMed
  89. Pulsifer AR, et al. 2020. Infect Immun. 88:00:00. PubMed
  90. Mueller-Leisse J, et al. 2015. Med Mycol. 53: 622-629. PubMed
  91. Pliyev B, et al. 2011. Cell Immunol. 271:214. PubMed
  92. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  93. Bonegio RG, et al. 2019. J Immunol. 202:675. PubMed
  94. Little M, et al. 2012. PLoS One. 7:e28626.. PubMed
  95. Rodriguez‐Meira A et al. 2019. Molecular cell. 73(6):1292-1305 . PubMed
  96. Ceglia V, et al. 2022. Front Immunol. 12:786144. PubMed
RRID
AB_314496 (BioLegend Cat. No. 305104)
AB_314495 (BioLegend Cat. No. 305103)

Antigen Details

Structure
Ig superfamily, CEA antigen group, GPI-linked glycoprotein, 95-100 kD
Distribution

Granulocytes

Function
Cell adhesion, neutrophil activation
Ligand/Receptor
CD66c
Cell Type
Granulocytes, Neutrophils
Biology Area
Immunology
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Kuijpers T, et al. 1993. J. Immunol. 151:4934.
2. Kuroki M, et al. 1992. J. Leuk. Biol. 52:551.

Gene ID
1088 View all products for this Gene ID
UniProt
View information about CD66b on UniProt.org

Related FAQs

There are no FAQs for this product.

Customers Also Purchased

PE anti-human CD19
Clone: HIB19

PE anti-human CD16
Clone: 3G8

PE anti-human CD14
Clone: M5E2

FITC anti-human CD45
Clone: HI30

Go To Top Version: 2    Revision Date: 01-05-2017

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
G10F5 (See other available formats)
Regulatory Status
RUO
Workshop
VI MA81
Other Names
CD67, CGM6, NCA-95, CEACAM8
Isotype
Mouse IgM, κ
Ave. Rating
Submit a Review
Product Citations
publications
G10F5
Human peripheral whole blood granulocytes stained with G10F5 FITC
  • G10F5
    Human peripheral whole blood granulocytes stained with G10F5 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
305104 100 tests SEK1958
Check Availability


Need larger quantities of this item?
Request Bulk Quote
305103 25 tests SEK824
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD66b is a 95-100 kD glycosylphosphatidylinositol (GPI)-linked protein also known as CD67, CGM6, and NCA-95. CD66b is a member of the immunoglobulin superfamily, carcinoembryonic antigen (CEA)-like subfamily. CD66b, expressed on granulocytes, has been reported to induce activation in neutrophils and to be involved in heterophilic adhesion with CD66c.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen, formalin-fixed paraffin-embedded tissue sections, and spatial biology (IBEX)5,6.

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Kishimoto T, et al. Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. London.
  3. Norling LV, et al. 2012. Arterioscler Thromb Vasc Biol. 32:1970. PubMed
  4. Meinke P, et al. 2015. Neuroimmunol Discord. 25:127. PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Ackermann M, et al. 2018. Nat Commun. 9:5088. PubMed
  2. Stojkov D, et al. 2017. J Cell Biol. 216:4073. PubMed
  3. Nijnik A, et al. 2010. J Immunol. 184:2539. PubMed
  4. Guo Y, et al. 2021. Exp Ther Med. 353:21. PubMed
  5. Carre C, et al. 2021. iScience. 24:102970. PubMed
  6. Kfoury Y, et al. 2021. Cancer Cell. 39:1464. PubMed
  7. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  8. Mauracher LM, et al. 2023. Res Pract Thromb Haemost. 7:100126. PubMed
  9. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  10. Margaroli C, et al. 2021. Cell Reports Medicine. 2(4):100239. PubMed
  11. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  12. Schimek V, et al. 2022. Cell Death Dis. 13:113. PubMed
  13. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  14. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
  15. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  16. Reif T, et al. 2021. Cell Reports Medicine. 2(6):100317. PubMed
  17. Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
  18. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
  19. Appios A, et al. 2021. Bio Protoc. 11:e4044. PubMed
  20. Osorio FG et al. 2018. Cell reports. 25(9):2308-2316 . PubMed
  21. Heim C, et al. 2015. J Immunol. 194:3861. PubMed
  22. Callahan S, et al. 2020. Cell Microbiol. 22:e13210. PubMed
  23. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  24. Gomez I, et al. 2020. Nat Commun. 11:214. PubMed
  25. Miralda I, et al. 2020. Front Immunol. 11:497. PubMed
  26. Saha R, et al. 2021. Sci Rep. 11:18849. PubMed
  27. Simon SCS, et al. 2020. Oncoimmunology. 9:1727116. PubMed
  28. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  29. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  30. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  31. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  32. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  33. Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed
  34. Ozuna H, et al. 2021. Front Immunol. 12:707096. PubMed
  35. Fan Z, et al. 2020. STAR Protoc. 1:100012. PubMed
  36. Franco LM, et al. 2019. J Exp Med. 216:384. PubMed
  37. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  38. SenGupta S, et al. 2016. J Leukoc Biol. 100: 1047 - 1059. PubMed
  39. Rodriguez-Meira A, et al. 2020. STAR Protoc. 1:100125. PubMed
  40. Zhao Z, et al. 2019. J Immunol Res. 2019:9561350. PubMed
  41. Pulsifer AR, et al. 2020. Infect Immun. 88:00:00. PubMed
  42. Mueller-Leisse J, et al. 2015. Med Mycol. 53: 622-629. PubMed
  43. Pliyev B, et al. 2011. Cell Immunol. 271:214. PubMed
  44. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  45. Bonegio RG, et al. 2019. J Immunol. 202:675. PubMed
  46. Little M, et al. 2012. PLoS One. 7:e28626.. PubMed
  47. Rodriguez‐Meira A et al. 2019. Molecular cell. 73(6):1292-1305 . PubMed
  48. Ceglia V, et al. 2022. Front Immunol. 12:786144. PubMed
  49. Ackermann M, et al. 2018. Nat Commun. 9:5088. PubMed
  50. Stojkov D, et al. 2017. J Cell Biol. 216:4073. PubMed
  51. Nijnik A, et al. 2010. J Immunol. 184:2539. PubMed
  52. Guo Y, et al. 2021. Exp Ther Med. 353:21. PubMed
  53. Carre C, et al. 2021. iScience. 24:102970. PubMed
  54. Kfoury Y, et al. 2021. Cancer Cell. 39:1464. PubMed
  55. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  56. Mauracher LM, et al. 2023. Res Pract Thromb Haemost. 7:100126. PubMed
  57. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  58. Margaroli C, et al. 2021. Cell Reports Medicine. 2(4):100239. PubMed
  59. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  60. Schimek V, et al. 2022. Cell Death Dis. 13:113. PubMed
  61. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  62. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
  63. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  64. Reif T, et al. 2021. Cell Reports Medicine. 2(6):100317. PubMed
  65. Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
  66. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
  67. Appios A, et al. 2021. Bio Protoc. 11:e4044. PubMed
  68. Osorio FG et al. 2018. Cell reports. 25(9):2308-2316 . PubMed
  69. Heim C, et al. 2015. J Immunol. 194:3861. PubMed
  70. Callahan S, et al. 2020. Cell Microbiol. 22:e13210. PubMed
  71. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  72. Gomez I, et al. 2020. Nat Commun. 11:214. PubMed
  73. Miralda I, et al. 2020. Front Immunol. 11:497. PubMed
  74. Saha R, et al. 2021. Sci Rep. 11:18849. PubMed
  75. Simon SCS, et al. 2020. Oncoimmunology. 9:1727116. PubMed
  76. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  77. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  78. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  79. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  80. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
  81. Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed
  82. Ozuna H, et al. 2021. Front Immunol. 12:707096. PubMed
  83. Fan Z, et al. 2020. STAR Protoc. 1:100012. PubMed
  84. Franco LM, et al. 2019. J Exp Med. 216:384. PubMed
  85. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  86. SenGupta S, et al. 2016. J Leukoc Biol. 100: 1047 - 1059. PubMed
  87. Rodriguez-Meira A, et al. 2020. STAR Protoc. 1:100125. PubMed
  88. Zhao Z, et al. 2019. J Immunol Res. 2019:9561350. PubMed
  89. Pulsifer AR, et al. 2020. Infect Immun. 88:00:00. PubMed
  90. Mueller-Leisse J, et al. 2015. Med Mycol. 53: 622-629. PubMed
  91. Pliyev B, et al. 2011. Cell Immunol. 271:214. PubMed
  92. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  93. Bonegio RG, et al. 2019. J Immunol. 202:675. PubMed
  94. Little M, et al. 2012. PLoS One. 7:e28626.. PubMed
  95. Rodriguez‐Meira A et al. 2019. Molecular cell. 73(6):1292-1305 . PubMed
  96. Ceglia V, et al. 2022. Front Immunol. 12:786144. PubMed
RRID
AB_314496 (BioLegend Cat. No. 305104)
AB_314495 (BioLegend Cat. No. 305103)

Antigen Details

Structure
Ig superfamily, CEA antigen group, GPI-linked glycoprotein, 95-100 kD
Distribution

Granulocytes

Function
Cell adhesion, neutrophil activation
Ligand/Receptor
CD66c
Cell Type
Granulocytes, Neutrophils
Biology Area
Immunology
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Kuijpers T, et al. 1993. J. Immunol. 151:4934.
2. Kuroki M, et al. 1992. J. Leuk. Biol. 52:551.

Gene ID
1088 View all products for this Gene ID
UniProt
View information about CD66b on UniProt.org

Customers Also Purchased

PE anti-human CD19
Clone: HIB19

PE anti-human CD16
Clone: 3G8

PE anti-human CD14
Clone: M5E2

FITC anti-human CD45
Clone: HI30

Go To Top Version: 2    Revision Date: 01-05-2017

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account